White House health advisor concerned coronavirus vaccine immunity won’t last forever

Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Disease (NIAID) and White House public health advisor, is concerned that a potential vaccine to protect against the novel coronavirus, COVID-19, may not deliver long-term immunity.

Fauci relayed his concerns in an interview with Howard Bauchner, editor of JAMA. Specifically, Fauci said he is “cautiously optimistic” about a vaccine, but that it will take several months before scientists can prove a vaccine works.

There are a handful of ongoing clinical trials to test the efficacy of a COVID-19 vaccine. Scientists hope to have a vaccine by the beginning of 2021, CNBC reported. Fauci is hopeful the U.S. will have several hundred million doses available by then.

“When you look at the history of coronaviruses, the common coronaviruses that cause the common cold, the reports in the literature are that the durability of immunity that’s protective ranges from three to six months to almost always less than a year,” Fauci said. “That’s not a lot of durability and protection.”

Further, there are still major questions about how immune systems respond to the virus once a person is exposed, CNBC reported.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

California-based Acutus Medical has said its ongoing agreement to manufacture and distribute left-heart access devices for Medtronic is the company's only source of revenue. 

The scam took place over a period of seven years, resulting in Medicare being billed for more than $70 million in fraudulent claims for unnecessary scans. 

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.